Quick Answer
Neuphoria Therapeutics Inc. reported Diluted EPS of $0.23 per share (loss) for fiscal year 2025.
Neuphoria Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.23 | +98.8% |
| 2024 | -$18.62 | -93000.0% |
| 2023 | -$0.02 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.77 | +57.0% | +82.5% |
| September 30, 2025 | -$4.41 | -611.3% | -167.3% |
| March 31, 2025 | $6.55 | +331.4% | +465.9% |
| December 31, 2024 | -$1.79 | +66.3% | -188.7% |
| September 30, 2024 | -$0.62 | — | +78.1% |
| March 31, 2024 | -$2.83 | — | +46.7% |
| December 31, 2023 | -$5.31 | — | — |
| September 30, 2023 | $0.00 | — | — |
- Neuphoria Therapeutics Inc. showed an increase of +98.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Neuphoria Therapeutics Inc.’s diluted eps has declined by 1050.0% (from $0.02 per share (loss) to $0.23 per share (loss)).
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: